Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 3

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 17Genitourinary 11Breast 9Gynecologic 3Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × disitamab vedotin × Gynecologic × Clear all
NCT06540729 2025-07-08

DAB

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
39 enrolled
Gynecologic

Ovarian Neoplasms

NCT06558682 2025-04-01

Neoadjuvant Therapy in Cervical Cancer

Qilu Hospital of Shandong University

Phase NA Recruiting
48 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡